公开(公告)号：US20180127413A1

公开(公告)日：2018-05-10

申请号：US15573141

申请日：2016-05-11

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Claude A. QUESNELLE ,  Lalgudi S. Harikrishnan ,  Matthew D. Hill

IPC: C07D471/04 ,  A61P35/02

Abstract: The present invention is directed to tricyclic compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

公开(公告)号：US20250163104A1

公开(公告)日：2025-05-22

申请号：US18715382

申请日：2022-12-02

Applicant: Bristol-Myers Squibb Company

Inventor： Jennifer X. QIAO ,  Michael A. POSS ,  Martin Patrick ALLEN ,  Claudio MAPELLI ,  Claude A. QUESNELLE ,  David R. TORTOLANI ,  Tammy C. WANG ,  Tao WANG ,  Yong ZHANG ,  Yunhui ZHANG ,  Zhongxing ZHANG

IPC: C07K7/56 ,  A61K38/12

Abstract: In accordance with the present disclosure, macrocyclic compounds have been discovered that bind to PD-I and are capable of inhibiting the interaction of PD-I with PD-LI. These macrocyclic compounds exhibit in vitro immunomodulatory efficacy thus making them therapeutic candidates for the treatment of various diseases including cancer and infectious diseases.